Vanda Pharmaceuticals (NASDAQ:VNDA) Issues Earnings Results, Beats Expectations By $0.06 EPS

Vanda Pharmaceuticals (NASDAQ:VNDA) issued its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.06, Zacks reports. The business had revenue of $53.19 million for the quarter, compared to analysts’ expectations of $51.00 million. Vanda Pharmaceuticals had a negative return on equity of 3.02% and a negative net margin of 8.59%. Vanda Pharmaceuticals updated its FY 2030 guidance to EPS and its FY 2025 guidance to EPS.

Vanda Pharmaceuticals Stock Performance

VNDA traded down $0.28 on Friday, hitting $4.42. 1,978,333 shares of the company were exchanged, compared to its average volume of 559,972. The firm has a fifty day simple moving average of $4.62 and a two-hundred day simple moving average of $4.87. Vanda Pharmaceuticals has a 12 month low of $3.71 and a 12 month high of $6.75. The stock has a market capitalization of $257.73 million, a PE ratio of -15.79 and a beta of 0.74.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on VNDA shares. HC Wainwright reissued a “buy” rating and set a $18.00 price objective on shares of Vanda Pharmaceuticals in a report on Tuesday, February 4th. StockNews.com started coverage on Vanda Pharmaceuticals in a research note on Wednesday, February 5th. They issued a “hold” rating on the stock.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.